Treatment of experimental murine candidiasis with liposome-associated amphotericin B
- 1 January 1984
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 22 (2) , 163-166
- https://doi.org/10.1080/00362178485380251
Abstract
Mice were challenged intravenously with Candida albicans, and then treated either with nothing (controls), amphotericin B-desoxycholate (AMB), or amphotericin B associated with liposomes (AMB-lipo). AMB-lipo permitted larger doses of amphotericin B to be given, and also appeared to have no severe toxicity in the animal model. High doses of AMB-lipo were protective, but at equal doses, AMB-lipo was not as effective as commercial AMB. Des souris sont inoculées par voie intraveineuse par Candida albicans puis traitées soit avec rien (contrôles), soit avec de l'amphotéricine B—désoxycholate (AMB) ou de l'amphotéricine B associée aux liposomes (AMB-lipo). L'AMB-lip permet de donner de plus fortes doses d'amphotéricine B et de plus, il ne semble pas être très toxique pour l'animal modèle. De fortes doses d'AMB-lipo sont protectrices mais, à doses égales, l'AMB-lipo n'est pas aussi efficace que l'AMB du commerce.Keywords
This publication has 3 references indexed in Scilit:
- Treatment and Prophylaxis of Disseminated Infection Due to Candida albicans in Mice with Liposome-Encapsulated Amphotericin BThe Journal of Infectious Diseases, 1983
- Excretion Pathways of Amphotericin BThe Journal of Infectious Diseases, 1979
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959